Thoracic Aortic Aneurysms

Thoracic aortic aneurysms are dilations of the aortic wall in the thoracic region, which are life-threatening diseases. Thoracic aortic aneurysms can go unnoticed until it is too late, which is why it is deemed a "silent killer." Here at Protheragen, we work on improving therapies for rare diseases, particularly thoracic aortic aneurysms. We are one of the leading research service providers in the industry, offering end-to-end drug development services.

Introduction to Thoracic Aortic Aneurysms

A thoracic aortic aneurysm represents a disease condition that blends subtle features with the potential for sudden, life-threatening complications, including dissection and rupture of the thoracic aorta, leading to death. In the majority of instances, thoracic aortic aneurysm does not present with clear, notable features prior to the onset of severe complications or death. The epidemiological data concerning thoracic aortic aneurysm show its prevalence as 0.16-0.34% and incidence as 7.6 per 100,000 person-years.

Fig.1 Maintenance of aorta structure and function requires proper expression of Notch component genes. (Malashicheva, A., et al., 2020)

Pathogenesis of Thoracic Aortic Aneurysms

The thoracic aortic aneurysm pathogenic mechanisms are diverse and include more common degenerative or hypertensive processes linked with aortic enlargement and, more rarely encountered, genetic disorders, for example, Marfan syndrome or Ehlers-Danlos syndrome, along with other syndromic connective tissue disorders. The molecular and genetic underpinnings of thoracic aortic aneurysms involve primarily transforming growth factor beta signaling, smooth muscle cell contractile systems and metabolism genes, and genes coding for the extracellular matrix. In some of the more recent studies, Notch signaling, among other pathways, has become important in the consideration of disease pathogenesis.

Fig.2 Classification of thoracic aortic aneurysms. (Malashicheva, A., et al., 2020)

Therapeutics Development for Thoracic Aortic Aneurysms

Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a therapy plan recommendation. For guidance on therapy options, please visit a regular hospital.

Our Services

Protheragen's entire set of services aids in the development of a medication for rare cardiovascular diseases. It includes modern diagnostics, advanced therapeutics, and the development of innovative disease models that target the specific issues of rare cardiovascular diseases. We offer complete support from identification and validation of targets to preclinical development to ensure strong and efficient advancement of your drug candidates. We also offer complete preclinical research services that cover pharmacokinetics and evaluation of drug safety.

Therapeutic Development Services

Diverse Platforms

• Small Molecule Drug Development
• Gene Therapy Development
• Therapeutic Peptide Development

• Cell Therapy Development
• Therapeutic Antibody Development
• Therapeutic Protein Development

Animal Model Development for Thoracic Aortic Aneurysms

The creation of different animal models for thoracic aortic aneurysm is essential for deepening our comprehension of the condition, discovering new intervention strategies, and streamlining the preclinical evaluation of novel therapeutics. We focus on offering tailored animal model development that covers numerous types of models, adapting them to the specific requirements of the research objectives posed by our clients.

Chemical-Induced Model

• Angiotensin II-Induced Model
• BAPN-Induced Model
• Elastase-Induced Model
• Calcium Chloride-Induced Model
• Other Models

Surgical Animal Model

• Transverse Aortic Constriction
• Pericardium Pouch Method
• Cover-Then-Cut Method
• Media and Intima Resection
• Other Models

Genetically Engineered Model

• Fbn1^C1041G/+ Model
• Fbn1^mgR/mgR Model
• Tgfbr2^SMKO Model
• Idua^-/- Model
• Other Models

Collaborating with Protheragen provides a unique benefit in the field of developing therapeutics for rare cardiovascular diseases. Our extensive scientific knowledge, paired with our unique all-inclusive service model, strategically mitigates the multifaceted difficulties typical of rare disease research. We are fueled by the desire to innovate, as well as a commitment to unparalleled quality, ensuring that all clients are supported throughout the entire process. Should you wish to discuss our services, please contact us.

Reference

• Malashicheva, Anna et al. "Notch signaling in the pathogenesis of thoracic aortic aneurysms: A bridge between embryonic and adult states." Biochimica et biophysica acta. Molecular basis of disease 1866.3 (2020): 165631.